Patient
SITE005-0139
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE005 (FRA) (Dr. Muller)
consented 2026-02-13
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 202); relationship: NOT RELATED
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 198); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 145); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 121); relationship: NOT RELATED
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-06 (study day 47); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 40); relationship: not assessed
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 40); relationship: not assessed
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-23 (study day 3); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.